^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN Kidney Cancer Panel has included erlotinib as a category 2A option, useful under certain circumstances, for first-line therapy for patients with relapsed or medically unresectable stage IV non-clear cell RCC.
